Why the study?
Does transcatheter tricuspid edge-to-edge repair (T-TEER) improve mortality and perioperative outcomes compared to surgical repair in Medicare beneficiaries with tricuspid regurgitation?
Does transcatheter tricuspid edge-to-edge repair (T-TEER) improve mortality and perioperative outcomes compared to surgical repair in Medicare beneficiaries with tricuspid regurgitation?
In Medicare beneficiaries with tricuspid regurgitation, T-TEER offers comparable 2-year mortality to surgical repair with better perioperative safety, though it carries a higher risk of subsequent valve reintervention.
T-TEER was associated with perioperative benefits over surgery despite higher reinterventions; leaves open its role pending randomized data.
Among Medicare beneficiaries with TR, the 2-year mortality rate was comparable between T-TEER and surgical repair. T-TEER showed advantages in perioperative outcomes, including lower in-hospital mortality and pacemaker implantation rates, whereas tricuspid valve reinterventions were more frequent in the T-TEER group. Further studies are necessary to refine indications, patient selections, and optimal timing for intervention with either treatment strategy.
No takes yet. Share an insight, caveat, or question.
Shimoda et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: